ASH 2022 Conference Coverage
Avatar

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamibarotene + Venetoclax & Azacitidine in RARA+ Newly Diagnosed AML Patients Ineligible for Standard Induction Chemo

By ASH 2022 Conference Coverage FEATURING Eytan Stein
By ASH 2022 Conference Coverage FEATURING Eytan Stein
167 views
December 16, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Recommended

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
21:05

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

3.3K views

·

8 months ago
22:37

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

2.2K views

·

9 months ago
19:01

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

574 views

·

2 months ago
27:49

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

694 views

·

3 months ago
17:51

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

882 views

·

6 months ago
19:21

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

488 views

·

4 months ago
27:26

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

449 views

·

4 months ago
21:51

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

526 views

·

2 months ago
28:02

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

726 views

·

6 months ago
22:30

Emerging Treatment Options for AML in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Perl

686 views

·

8 months ago
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

878 views

·

6 months ago
09:51

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

463 views

·

8 months ago
02:01

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

317 views

·

3 months ago
34:57

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju

435 views

·

5 months ago
04:16

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

394 views

·

5 months ago
48:04

Integrating Targeted Therapies in AML

Icahn School of Medicine at Mount Sinai

H. Kantarjian

409 views

·

5 months ago
14:39

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

496 views

·

8 months ago
14:58

ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger Patien…

2024 ASCO® Annual Meeting Insights Hub

C. McMahon

288 views

·

4 months ago
10:06

Current Treatment Landscape in BPDCN

Cristina Papayannidis

351 views

·

5 months ago
AUTOPLAY